Inloggen

Login
 
Wachtwoord vergeten?

Zealand Pharma (ZEAL)

167 Posts
Pagina: «« 1 ... 4 5 6 7 8 9 | Laatste | Omlaag ↓
  1. rbot 27 januari 2020 15:52
    Dasiglucagon (glucagon analog stable in liquid formulation) for use in other indications
    Dasiglucagon is a Zealand-invented glucagon analog with a unique stability profile in a ready-to-use aqueous solution. It is also in development for two additional indications: treatment of type 1 diabetes with a next-generation artificial pancreas, and treatment for children born with a genetic mutation that causes congenital hyperinsulinism (CHI).

    About type 1 diabetes and hypoglycemia
    People with type 1 diabetes suffer from insulin deficiency and inappropriate glucagon secretion. Both hormones are essential to ensure stable and healthy blood glucose levels. Consequently, patients must monitor and adjust their blood glucose levels to remain in proper glycemic control, as both high and low blood glucose may affect their health, both in the short and long term.

    Severe hypoglycemia is an acute, life-threatening condition resulting from a critical drop in blood glucose levels associated primarily with insulin therapy. Severe hypoglycemia occurs most frequently in people with type 1 diabetes due to injecting insulin multiple times daily. It is the biggest concern for insulin-dependent patients and the most feared complication of diabetes treatment. The condition is characterized by confusion, seizures, and often loss of consciousness that can result in death if left untreated.

    When a patient has a hypoglycemic event, a second person must assist in treatment. Currently marketed formulations of glucagon for the treatment of severe hypoglycemia require mixing first by the person assisting to treat and then immediate administration due to poor drug stability. Dasiglucagon is being developed to offer a stable ready-to-use rescue treatment for severe hypoglycemia.
  2. rbot 13 februari 2020 17:15
    Ja het gaat als een trein! Soms is het best om de rit lekker uit te zitten, hoewel ik soms wel wat hoogtevrees krijg.. Maar ben niet van plan te verkopen.

    Ik denk dat ze ook wel een overname kandidaat zijn namelijk.

    Goed om te onthouden dat de marketcap ondanks de grote stijging nog meevalt. <1.5 miljard

167 Posts
Pagina: «« 1 ... 4 5 6 7 8 9 | Laatste |Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum

Indices

AEX 651,73 -0,75%
EUR/USD 1,2081 -0,59%
Germany30^ 13.771,50 -1,55%
Gold spot 1.828,41 0,00%
LDN100-24h 6.700,03 0,00%
NY-Nasdaq Composite 12.998,50 -0,87%

Stijgers

Aegon
+3,30%
Flow T...
+2,36%
Accell
+2,01%
Wereld...
+1,90%
Ahold ...
+1,51%

Dalers

Alfen ...
-7,45%
JUST E...
-4,72%
VIVORY...
-4,60%
BESI
-3,72%
JDE PE...
-3,29%
 
Quotedata: Amsterdam realtime by Euronext, other realtime by Cboe Europe Ltd.   US stocks: by NYSE & Cboe BZX Exchange, 15min delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by Infront. Crypto data by Crypto Compare